À̾Ⱥ¹ ¸íÀÇ

À¯¹æ¾ÏÀÇ »õ·Î¿î Ä¡·á ±âÁØÀ» Á¦½ÃÇÏ´Â ÀþÀº ¸íÀÇ

À̾Ⱥ¹ ¸íÀÇ

  • ¼Ò ¼Ó
    Áß¾Ó´ëÇб³ ±¤¸íº´¿ø À¯¹æ³»ºÐºñ¿Ü°ú
  • Àü¹®ºÐ¾ß
    À¯¹æ¾Ï, ¾ç¼ºÀ¯¹æÁúȯ

´ëÇѿܰúÇÐȸ Æò»ýȸ¿øÀÌÀÚ Çѱ¹À¯¹æ¾ÏÇÐȸ, ´ëÇѰ©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ, ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ Á¤È¸¿øÀ¸·Î Ȱµ¿Çϸç, Çѱ¹À¯¹æ¾ÏÇÐȸ ÆíÁýÀ§¿øÈ¸ ºÎÆíÁýÀå°ú ÀÓ»ó½ÃÇèÀ§¿øÈ¸ À§¿øÀ» ¸Ã°í ÀÖ´Ù. À¯¹æ¾ÏÀÇ ¸ÂÃãÇü Ä¡·á, ³»½Ã°æ¡¤·Îº¿¼ö¼ú, Ç׾ϡ¤Ç¥ÀûÄ¡·á ¹ÝÀÀ ¿¹Ãø ¿¬±¸¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, ¡®The Breast¡¯ µî ±¹Á¦ÇмúÁö¿¡ ´Ù¼öÀÇ ³í¹®À» °ÔÀçÇß´Ù. 2018³â ±¹Á¦À¯¹æ¾ÏÇÐȸ(GBCC) ¿ì¼öÆ÷½ºÅÍ»ó°ú 2021³â µÎ»ê¿¬°­¿Ü°úÇмú»ó°úÀ» ¼ö»óÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ Çлç
  • °æÈñ´ëÇб³ Àǰú´ëÇпø ¼®»ç
  • °æÈñ´ëÇб³ Àǰú´ëÇпø ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) Áß¾Ó´ëÇб³±¤¸íº´¿ø ¿Ü°úÀå
  • úÞ) Áß¾Ó´ëÇб³±¤¸íº´¿ø ¿Ü°ú ±³¼ö
  • Áß¾Ó´ëÇб³±¤¸íº´¿ø ¿Ü°ú ÀÓ»ó±³¼ö
  • ºÎ»ê¹éº´¿ø ¿Ü°ú ºÎ±³¼ö
  • ºÎ»ê¹éº´¿ø ¿Ü°ú Á¶±³¼ö
  • ÀÌ´ë¸ñµ¿º´¿ø ¿Ü°ú ÀüÀÓÀÇ ¹× ÀÓ»óÁ¶±³¼ö
  • ÀÌ´ë¸ñµ¿º´¿ø ¿Ü°ú ·¹Áö´øÆ®
  • ÀÌ´ë¸ñµ¿º´¿ø ÀÎÅÏ

¼ö»ó³»¿ª

Awards List
  • µÎ»ê¿¬°­¿Ü°úÇмú»ó(2021)
  • ±¹Á¦ À¯¹æ¾Ï ÇÐȸ(GBCC) ¿ì¼ö Æ÷½ºÅÍ»ó(2018)

ÇÐȸȰµ¿

Academic activities
  • ´ëÇÑ ¿Ü°úÇÐȸ Æò»ýȸ¿ø
  • Çѱ¹ À¯¹æ¾ÏÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ °©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Á¤È¸¿ø
  • ´ëÇÑ Á¾¾ç¿Ü°úÇÐȸ Á¤È¸¿ø
  • Çѱ¹À¯¹æ¾ÏÇÐȸ ÆíÁýÀ§¿øÈ¸ ºÎÆíÁýÀå(Journal of breast cancer)
  • Çѱ¹À¯¹æ¾ÏÇÐȸ ÀÓ»ó½ÃÇèÀ§¿øÈ¸ À§¿ø
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö The Breast 72
Á¦ ¸ñ Hypofractionated Radiotherapy for Early-Stage Breast Cancer: A Propensity Score Matched Analysis
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Journal of Korean Medical Science 37 (8)
Á¦ ¸ñ Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Cancer Immunology, Immunotherapy, 1-12
Á¦ ¸ñ Synergism of a novel MCL 1 downregulator, acriflavine, with navitoclax in triple negative breast cancer, lung adenocarcinoma and glioblastoma multiforme
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö International journal of oncology 60 (1), 1-12
Á¦ ¸ñ Postpartum Galactocele in Augmented Breast after Using Breast Pump Mimicking Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Journal of the Korean Society of Radiology 82 (6), 1570-1574
Á¦ ¸ñ Enlightening the immune mechanism of the abscopal effect in a murine HCC model and overcoming the late resistance with Anti-PD-L1
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö International Journal of Radiation Oncology Biology Physics 110 (2), 510-520
Á¦ ¸ñ Induction of Triple-negative Breast Cancer Cells to Immunogenic Cell Death and Increase Cross-Presentation by Streptomyces sanyensis
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Pharmacognosy Research 13 (3)

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

Áß¾Ó´ëÇб³ ±¤¸íº´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1811-7800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

Áß¾Ó´ëÇб³±¤¸íº´¿øÀº KTX±¤¸í¿ª ÀαÙÀÇ 700º´»óÀ» °®Ãá Á¾ÇÕÀÇ·á±â°üÀÌ´Ù. ¾Ïº´¿ø¡¤½ÉÀå³úÇ÷°üº´¿ø¡¤Ã´Ãß¼¾ÅÍ¡¤°üÀý¼¾ÅÍ¡¤È£Èí±â¾Ë·¹¸£±â¼¾ÅÍ¡¤¼ÒÈ­±â¼¾ÅÍÀÇ 6°³ ÁßÁõŬ·¯½ºÅ͸¦ ¿î¿µÇϰí ÀÖ´Ù. ¼öµµ±Ç ÁßÁõÀÇ·áü°èÀÇ Áß½ÉÀ» ´ã´çÇÏ´Â '¼ö¼ú ÀßÇÏ´Â º´¿ø'À¸·Î °Åµì³ª°í ÀÖÀ¸¸ç, ÀÇ·á±â°üÀÇ µðÁöÅÐ ÀüȯÀ» ¼±µµÇϸç ÃÖ°í¼öÁØÀÇ °æÀï·ÂÀ» È®º¸Çß´Ù.

Áß¾Ó´ëÇб³ ±¤¸íº´¿ø À̹ÌÁö

°æ±âµµ ±¤¸í½Ã ´ö¾È·Î 110

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä